Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Such a delight to host the latest episode of the JAMA Oncology podcast!
If you’re looking for insightful, cutting-edge discussions, this one’s perfect for your morning drive.
In this episode, I sit down with Dr. Michael Postow, MD From the Memorial Sloan Kettering Cancer Center author of “Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy.”
This is hosted in American Medical Association Ed Hub.
We dive into the groundbreaking use of Nobel Prize-winning immunotherapy drugs in the treatment of melanoma brain metastases—a major advancement in cancer care.”